Nanopath secures $10 million to develop diagnostic testing for women

Nanopath secures $10 million in series A funding to develop and commercialise diagnostic testing for women’s health screening.

The funding will support development and commercialisation of Nanopath’s bio-sensing platform that aims to transform how women’s pelvic and gynaecological infections are diagnosed.

Amogha Tadimety, co-founder of Nanopath, said: “Nanopath’s mission is deeply rooted in improving women’s health and even more broadly, health equity for all. We envision Nanopath’s technology as the go-to platforms for route women’s health screening, allowing for clinically actionable diagnosis within a single office visit.

“With this funding, we’re looking to build our technical team and initiate commercial and clinical partnership to bring our technology platform to market.”

Nanopath’s bio-sensing technology utilises ultra-sensitive optical detection to identify DNAs and RNAa, without the need for nucleic acid amplification.

This amplification-free approach minimises reagents, lower costs and reduces user steps that are ubiquitous across molecular diagnostics. Nanopath’s platform will require minimal training to operate, making high-complexity molecular diagnostics testing accessible at the point-of-care.

“What we are building has the potential to holistically improve patient care by circumventing existing complex, expensive and time-consuming workflows, while simultaneously providing more granular health information,” said Alison Burklund, co-founder of Nanopath. 

“We started in the women’s health space because of the deep unmet need, and our desire as founders to bring a first-in-class diagnostic platform to a population that has been consistently overlooked.

“That said, our technology has the potential to be valuable in any situation where DNA or RNA detection is useful, including respiratory disease diagnosis, characterisation of generic risk factors, and even biosecurity surveillance and environmental monitoring.”

Nanopath’s technology has the potential to simultaneously test for multiple pathogens, based on presenting symptoms, and reduce delivery of test results from days to just 15 minutes.

The company has generated strong pilot clinical data in its two lead indications through collaborations with leading hospital systems in New England.